Characteristics of chronically infected hepatitis B virus (HBV) cohort
| Number of patients (total) | 960 |
| Age at the beginning of follow-up: median (range) | 36 (2–80) |
| Gender (%) | |
| Male | 502 (52.3) |
| Female | 389 (40.5) |
| Unknown | 69 (7.2) |
| Ethnicity (%) | |
| White | 106 (11.0) |
| Mixed | 11 (1.2) |
| Asian | 220 (22.9) |
| Black | 161 (16.8) |
| Other | 72 (7.5) |
| Unknown | 390 (40.6) |
| HDV coinfection | |
| Yes (%) | 17 (1.8) |
| No (%) | 468 (48.7) |
| Unknown (%) | 475 (49.5) |
| HCV coinfection | |
| Yes (%) | 75 (7.8) |
| No (%) | 347 (36.1) |
| Unknown (%) | 538 (56.1) |
| HIV coinfection | |
| Yes (%) | 7 (0.7) |
| No (%) | 427 (44.5) |
| Unknown (%) | 526 (54.8) |
| Documented comorbidities | |
| Diabetes (%) | 30 (3.1) |
| Depression (%) | 28 (2.9) |
| Chronic kidney disease (%) | 16 (1.7) |
| Coagulation disorder (%) | 22 (2.3) |
| Cryoglobulinaemia (%) | 3 (0.3) |
| Cancer (%) | 21 (2.2) |
| Liver cancer (%) | 1 (0.1) |
| Other cancer (%) | 20 (2.1) |
| Severity of liver disease | |
| Cirrhosis (%) | 27 (2.8) |
| Decompensated (%) | 4 (0.4) |
| Child–Pugh Score: median (IQR) | NA |
| Fibroscan stiffness: median (IQR) | 5.3 (2.4) |
| MELD Score: median (IQR) | NA |
| Patients treated (%)* | 254 (26.5) |
| Lab tests at baseline | |
| Alanine aminotransferase (IU/L) | |
| Untreated group: median (IQR) | 29 (25) |
| Treated group: median (IQR) | 39 (37) |
| HBV DNA (log10 IU/mL) | |
| Untreated group: median (IQR) | 3.15 (1.58) |
| Treated group: median (IQR) | 4.26 (3.67) |
| Hepatitis B e antigen positive | |
| Untreated group (%) | 82/706 (11.6) |
| Treated group (%) | 84/254 (33.1) |
For a continuous variable, median and the IQR are calculated, for a categorical variable, the number and the percentage of patients is provided.
*Patients who had at least one episode of treatment recorded.
MELD, Model For End-Stage Liver Disease; NA, not available.